RxDoctor Payments Data

Lawrence Adler, MD

Family Medicine · New York, NYNPI 1609898469

Payments from drug & device makers

$1,117in general payments, 2019–2025

Across 52 payments — averaging $21.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$814
  • GSK$70
  • Gilead$64
  • Amgen$64
  • Lilly USA, LLC$56
  • AbbVie$34
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$1,06796%
  • Education$504%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk35$814
GSK4$70
Gilead2$64
Amgen5$64
Lilly USA, LLC4$56
AbbVie1$34
Mayne Pharma Commercial LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,117 in reported general payments places this provider in the 65th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$109,033
Medicare patients
265
Services billed
1,380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala35$142,051
JardianceEmpagliflozin40$50,383
EliquisApixaban48$44,282
DescovyEmtricitabine/Tenofov Alafenam12$26,001
JanuviaSitagliptin Phosphate30$24,343
XareltoRivaroxaban25$23,073
OzempicSemaglutide12$20,366
MyrbetriqMirabegron15$18,833
LinzessLinaclotide14$10,207
SunosiSolriamfetol Hcl11$9,429
SymbicortBudesonide/Formoterol Fumarate30$8,468
FarxigaDapagliflozin Propanediol14$8,017
VyvanseLisdexamfetamine Dimesylate18$6,896
Breo ElliptaFluticasone/Vilanterol12$4,644
Albuterol Sulfate HfaAlbuterol Sulfate123$4,029

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$64$168,05247 claims
Novo NordiskOzempic$814$20,36612 claims
AbbVieLinzess$34$10,20714 claims
GSKBreo Ellipta$70$4,64412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,321 family medicine providers in New York.

Other family medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →